Tracy A Daniels

US Patent:

20110091466, Apr 21, 2011

Filed:

Oct 7, 2010

Appl. No.:

12/900256

Inventors:

MANUEL L. PENICHET - LOS ANGELES CA, US
BIRGIT C. SCHULTES - ARLINGTON MA, US
CHRISTOPHER F. NICODEMUS - CHARLESTOWN MA, US
TRACY R. DANIELS - WOODLAND HILLS CA, US
GUSTAVO HELGUERA - LONG BEACH CA, US
JOSE A. RODRIGUEZ - PARAMOUNT CA, US

International Classification:

A61K 39/395
A61P 35/00
C07K 16/18

US Classification:

4241391, 4241551, 4241561, 5303873, 5303879, 53038815, 5303888

Abstract:

The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).

US Patent:

20130022614, Jan 24, 2013

Filed:

Feb 14, 2012

Appl. No.:

13/372557

Inventors:

MANUEL L. PENICHET - LOS ANGELES CA, US
BIRGIT C. SCHULTES - ARLINGTON MA, US
CHRISTOPHER F. NICODEMUS - CHARLESTOWN MA, US
TRACY R. DANIELS - WOODLAND HILLS CA, US
GUSTAVO HELGUERA - LONG BEACH CA, US
JOSE A. RODRIGUEZ - PARAMOUNT CA, US

International Classification:

C07K 16/18
C07K 19/00
A61P 37/04
A61K 39/395

US Classification:

4241561, 5303888, 5303873, 53038815, 53038885, 5303879, 4241551, 5303911

Abstract:

The present invention provides monoclonal IgE antibodies comprising Fc epsilon (ε) constant regions and variable regions comprising at least one antigen binding region specific for binding a single epitope of a circulating, tumor-associated antigen (TAA) that is not a cell surface antigen wherein the epitope of the targeted antigen is not highly repetitive or is a non-repetitive epitope. The IgE antibodies of the invention are useful in the treatment of cancer associated with the tumor antigen. In one embodiment the TAA is prostate-specific antigen (PSA).

US Patent:

20130028891, Jan 31, 2013

Filed:

Apr 11, 2011

Appl. No.:

13/639172

Inventors:

Manuel L. Penichet - Los Angeles CA, US
Tracy R. Daniels - Los Angeles CA, US

Assignee:

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA - Oakland CA

International Classification:

A61K 39/395
A61P 35/00

US Classification:

4241331, 4241741, 4241431

Abstract:

Disclosed herein are methods and compositions for treating cancer. In particular, the in vivo efficacy of unconjugated anti-TfR antibodies, such as ch128.1, are disclosed herein.